Please login to the form below

Not currently logged in
Email:
Password:

Hanspeter Spek to retire from Sanofi

President of global operations will step down after 18 years at the pharma company

Hanspete Spek, SanofiSanofi's president of global oepraitons Hanspeter Spek is to retire.

His will step down in mid-2013 following 18 years service at the company he joined in 1985 as marketing director at Sanofi Pharma GmbH Germany.

Spek rose through the ranks , eventually being appointed to this current position in November, 2009.

“During his many years with Sanofi, Hanspeter has made an exceptional contribution to the success of the group and has helped bring Sanofi to the forefront of the industry,” said the company's CEO Christopher Viehbacher.

“His early recognition of growing opportunities in the emerging markets has contributed to the building of Sanofi's leading position there.”

During his time at Sanofi, he has helped with the success of several significant products, including bloodthinner Plavix, insulin Lantus and cancer drug Taxotere.

A succession plan is to be announced said Sanofi.

21st December 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics